

Date: 14/02/2023

To
Dept. of Corporate Services,
BSE Limited,
Floor 25, P J Tower, Dalal Street,
Mumbai - 400001.

Scrip Code: 526445

Dear Sir/Madam,

Sub: Outcome of the Board Meeting.

Ref: Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please refer our letter dated February 06, 2023 under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In continuation, we wish to inform that at the meeting of Board of Directors held today i.e., on February 14, 2023, the Directors have inter-alia considered and approved the following amongst other subject matters:

- Unaudited Financial Results (Standalone and Consolidated) with the Limited Review Report of the Company for the quarter and nine-months ended December 31, 2022 (Q3), pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Any other business.


We, herewith, have attached the copy of the unaudited financial results (standalone and consolidated) for the quarter and nine-months ended December 31, 2022 along with the Limited Review Report for the said period.

The Board Meeting commenced at 06 : 45 p.m. and concluded at 07: 45 p.m. The necessary arrangements are in place to publish the unaudited financial results in the newspapers. The said financial results will also be available on company's website www.indrayani.com and also on BSE website www.bseindia.com.


We request you to kindly take the same on your records.

Thanking you.

Yours faithfully,
For Indrayani Biotech Limited



Kasiraman Sayee Sundar
Managing Director
DIN: 01295584





Limited Review Report on consolidated unaudited quarterly to date financial results of the company Pursuant to the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015

To
The Board of Directors
Indrayani Biotech Limited

We have reviewed the accompanying Statement of Consolidated Financial Results of Indrayani Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income / loss of its associates for the quarter ended **31st December, 2022** and for the period from **1st April 2022 to 31st December 2022** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended **31st December, 2021** and corresponding period from 1st April 2021 to 31st December 2021 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to audit/review.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our review of such consolidated financial statements.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the unaudited results of the following entities:

- i. HSL Agri Solutions Limited – Subsidiary
- ii. IBL Healthcare Limited – Subsidiary
- iii. HSL Prime Properties Private Limited - Subsidiary
- iv. Dindigul Farm Product Private Limited – Subsidiary



VENKATESH & CO
Chartered Accountants

- v. Healthway India Private Limited – Step down Subsidiary
- vi. India Home Health Care Private Limited – Step down Subsidiary
- vii. IBL Thiruvannamalai LLP - Step down Subsidiary

Based on our review conducted and procedures performed as stated in paragraph above and based on the consideration of the reports of the management referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the financial statement / financial information of **4 Subsidiaries and 2 step down subsidiaries** included in the consolidated unaudited financial results, whose interim financial information for the Period ended 31st December, 2022 reflects total revenues of ₹ **8,554.29 Lakhs**, total comprehensive profit / (loss) of ₹ **638.13 Lakhs** for the period ended on that date and in respect of **M/s. IBL Thiruvannamalai LLP** (stepdown subsidiary) included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of ₹ **12.14 Lakhs**, total net profit / (Loss) after tax of ₹ **(10.19) Lakhs** for the period ended on that date, as considered in the consolidated financial results.

This financial information have been reviewed by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the Management and the procedures performed by us as stated in paragraph mentioned above.

for Venkatesh & Co

Chartered Accountants

FRN : 004636S

VIJAYA
RAGHAVAN
DASARATY
Digitally signed by
VIJAYA RAGHAVAN
DASARATY
Date: 2023.02.14
16:37:33 +05'30'

CA Dasaraty V

Partner

M No : 026336

UDIN: 23026336BGULCG1078

Chennai, 14th February 2023

"SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai- 600 017.

Telefax: 2814 4763/64/65/66 Email: audit@venkateshandco.com

INDRAYANI BIOTECH LIMITED

CIN: L40100TN1992PLC129301

Regd. Office :

BLOCK 1, MODULE NO.33, 3rd FLOOR,SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY CHENNAI - 600032

STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2022

Rs. in Lakhs

SR No	PARTICULARS	CONSOLIDATED					
		Quarter Ended		Nine Months Ended		Year Ended	
		31-12-2022	30-09-2022	31-12-2021	31-12-2022	31-12-2021	31-Mar-22
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	(a) Net Sales/Revenue from Operations	4,599.53	4,205.30	1,525.06	11,368.04	4,432.50	6,157.18
	(b) Other Income	7.86	196.41	15.29	243.66	21.55	22.08
	Total Income from Operations	4,607.38	4,401.71	1,540.35	11,611.69	4,454.05	6,179.26
2	Expenses						
	(a) Cost of Materials consumed	2,680.74	3,022.79	979.47	7,037.35	2,881.03	4,104.29
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	(281.94)	-	-	-	-
	(c) Employee benefits expenses	680.54	504.81	266.72	1,623.99	840.67	1,021.64
	(d) Finance Costs	121.06	115.16	59.27	333.16	144.42	187.97
	(e) Depreciation and amortisation expense	78.17	74.96	26.69	219.54	48.07	65.94
	(f) Other expenses	680.40	415.20	93.45	1,301.70	257.66	354.23
	Total Expenses	4,240.91	3,850.98	1,425.60	10,515.74	4,171.84	5,734.07
3	Total profit / (Loss) before exceptional items and tax	366.48	550.73	114.75	1,095.96	282.21	445.19
4	Exceptional Items						
	Add:Share of Profit In Associates	-	-	(0.21)	-	0.85	-
	Less: Written of CWIP	(25.00)	(25.00)	-	(50.00)	-	-
5	Total profit / (Loss) before tax	341.48	525.73	114.53	1,045.96	283.06	445.19
6	Total profit / (Loss) before tax						
7	Tax Expenses						
	Current Tax	-	-	-	-	-	1.24
	Deferred Tax	(2.69)	-	-	(2.69)	-	-
	Total Tax Expenses	(2.69)	-	-	(2.69)	-	1.24
8	Net Profit Loss for the period from continuing operations	344.17	525.73	114.53	1,048.65	283.06	443.95
9	Profit (loss) from discontinued operations before tax	-	-	-	-	-	-
10	Tax expense of discontinued operations	-	-	-	-	-	-
11	Net profit (loss) from discontinued operation after tax	-	-	-	-	-	-



K. Jagan Mohan

12	Share of profit (loss) of associates and joint ventures accounted for using equity method	-	-	-	-	-	-
13	Total profit (loss) for period	344.17	525.73	114.53	1,048.65	283.06	443.95
14	Other comprehensive income net of taxes	-	-	-	-	-	-
15	Total Comprehensive Income for the period attributable to	344.17	525.73	114.53	1,048.65	283.06	443.95
	Comprehensive income for the period attributable to owners of parent	245.77	502.55	118.36	765.60	292.03	442.75
	Total comprehensive income for the period attributable to Non-controlling Interests	98.40	23.18	(3.83)	283.05	(8.97)	1.20
16	Details of equity share capital						
	Paid-up equity share capital	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72
	Face value of equity share capital(Rs.)	10.00	10.00	10.00	10.00	10.00	10.00
17	Details of debt securities						
	Paid-up debt capital	-	-	-	-	-	-
	Face value of debt securities	-	-	-	-	-	-
18	Reserves excluding revaluation reserve						
19	Debenture redemption reserve	-	-	-	-	-	-
20	Earnings per share						
i	Earnings per equity share for continuing operations						
	Basic earnings (loss) per share from continuing operations	0.72	1.47	0.35	2.24	0.85	1.3
	Diluted earnings (loss) per share from continuing operations	0.72	1.47	0.35	2.24	0.85	1.3
ii	Earnings per equity share for discontinued operations						
	Basic earnings (loss) per share from discontinued operations	-	-	-	-	-	-
	Diluted earnings (loss) per share from discontinued operations	-	-	-	-	-	-
iii	Earnings per equity share						
	Basic earnings (loss) per share from continuing and discontinued operations	0.72	1.47	0.35	2.24	0.85	1.3
	Diluted earnings (loss) per share from continuing and discontinued operations	0.72	1.47	0.35	2.24	0.85	1.3

Notes:

- 1.The above financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors Directors at their meeting held on 14th February 2023 and have been subjected to Limited review by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- 2.The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com).
- 3.Figures for three months ended 31 December 2022 as reported in these financials results are the balancing figures between unaudited figures, in respect of the half year and the published year to date figures upto the third quarter of the current financial year.
4. There was one investor complaint received, resolved and disposed during the quarter.
5. Previous period figures have been regrouped wherever necessary.

Date : 14/02/2023
Place : Chennai



K. Jagan Mohan



VENKATESH & CO
Chartered Accountants

Limited Review Report on Quarterly Financial Results of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
Indrayani Biotech Limited

We have reviewed the accompanying statement of unaudited standalone financial results of **Indrayani Biotech Limited** ('the Company') for the quarter ended December 2022. This statement, is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for Venkatesh & Co
Chartered Accountants

FRN : 004636S

VIJAYA
RAGHAVAN
DASARATY
Date: 2023.02.14
16:36:23 +05'30'

CA Dasaraty V

Partner

M No : 026336

UDIN: 23026336BGULCF9555

Chennai, 14th Feb 2023

"SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai- 600 017.

Telefax: 2814 4763/64/65/66 Email: audit@venkateshandco.com

<p style="text-align: center;">INDRAYANI BIOTECH LIMITED CIN: L40100TN1992PLC129301 Regd. Office : BLOCK 1, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY CHENNAI - 600032</p>							
SR No	PARTICULARS	STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2022					
		Rs. In Lakhs					
		STANDALONE					
		Quarter Ended		Nine Months Ended		Year Ended	
		31-12-2022	30-09-2022	31-12-2021	31-12-2022	31-12-2021	31-Mar-22
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	(a) Net Sales/Revenue from Operations	2,165.60	1,592.16	1,463.31	5,317.56	4,318.70	5,798.85
	(b) Other Income	4.48	6.18	15.29	48.90	21.52	22.08
	Total Income from Operations	2,170.08	1,598.34	1,478.59	5,366.46	4,340.22	5,820.94
2	Expenses						
	(a) Cost of Materials consumed	1,173.68	765.95	973.24	2,905.97	2,868.48	3,971.31
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(c) Employee benefits expenses	543.09	391.29	233.75	1,278.73	767.77	897.29
	(d) Finance Costs	58.32	56.73	59.27	154.09	144.42	187.97
	(e) Depreciation and amortisation expense	17.48	15.82	8.86	44.97	25.73	34.43
	(f) Other expenses	185.57	214.02	85.63	512.01	226.54	307.38
	Total Expenses	1,978.15	1,443.81	1,360.76	4,895.77	4,032.93	5,398.38
3	Total profit / (Loss) before exceptional Items and tax	191.94	154.53	117.83	470.69	307.29	422.56
4	Exceptional Items						
	Add: Share of Profit In Associates	-	-	-	-	-	-
	Less: Written off CWIP	(25.00)	(25.00)	-	(50.00)	-	-
5	Total profit / (Loss) before tax	166.94	129.53	117.83	420.69	307.29	422.56
6	Total profit / (Loss) before tax	-	-	-	-	-	-
7	Tax Expenses						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
	Total Tax Expenses	-	-	-	-	-	-
8	Net Profit Loss for the period from continuing operations	166.94	129.53	117.83	420.69	307.29	422.56
9	Profit (loss) from discontinued operations before tax	-	-	-	-	-	-
10	Tax expense of discontinued operations	-	-	-	-	-	-
11	Net profit (loss) from discontinued operation after tax	-	-	-	-	-	-




K. Anjan Sundar

12	Share of profit (loss) of associates and joint ventures accounted for using equity method						
13	Total profit (loss) for period	166.94	129.53	117.83	420.69	307.29	422.56
14	Other comprehensive income net of taxes	-	-	-	-	-	-
15	Total Comprehensive income for the period attributable to	166.94	129.53	117.83	420.69	307.29	422.56
	Comprehensive income for the period attributable to owners of parent	166.94	129.53	117.83	420.69	307.29	422.56
	Total comprehensive income for the period attributable to Non-Controlling Interests	-	-	-	-	-	-
16	Details of equity share capital						
	Paid-up equity share capital	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72
	Face value of equity share capital (Rs.)	10.00	10.00	10.00	10.00	10.00	10.00
17	Details of debt securities						
	Paid-up debt capital	-	-	-	-	-	-
	Face value of debt securities	-	-	-	-	-	-
18	Reserves excluding revaluation reserve						
19	Debt redemption reserve	-	-	-	-	-	-
20	Earnings per share						
I	Earnings per equity share for continuing operations						
	Basic earnings (loss) per share from continuing operations	0.49	0.38	0.34	1.23	0.90	1.23
	Diluted earnings (loss) per share from continuing operations	0.49	0.38	0.34	1.23	0.90	1.23
II	Earnings per equity share for discontinued operations						
	Basic earnings (loss) per share from discontinued operations	-	-	-	-	-	-
	Diluted earnings (loss) per share from discontinued operations	-	-	-	-	-	-
III	Earnings per equity share						
	Basic earnings (loss) per share from continuing and discontinued operations	0.49	0.38	0.34	1.23	0.90	1.23
	Diluted earnings (loss) per share from continuing and discontinued operations	0.49	0.38	0.34	1.23	0.90	1.23

Notes:

1. The above financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 14th February 2023 and have been subjected to Limited review by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
2. The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com).
3. Figures for three months ended 31 December 2022 as reported in these financials results are the balancing figures between unaudited figures, in respect of the half year and the published year to date figures upto the third quarter of the current financial year.
4. There was one investor complaint received, resolved and disposed during the quarter.
5. Previous period figures have been regrouped wherever necessary.

Date : 14/02/2023
Place : Chennai



K. Anjan Reddy